Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Aethlon Medical (AEMD)

Aethlon Medical (AEMD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Aethlon Medical 11555 SORRENTO VALLEY ROAD SUITE 203 SAN DIEGO CA 92121 USA

www.aethlonmedical.com P: 619-941-0360

Description:

Aethlon Medical, Inc. is a development stage medical device company focused on expanding the applications of our Hemopurifier (R) platform technology, which is designed to rapidly reduce the presence of infectious viruses and other toxins from human blood. In this regard, its core focus is the development of therapeutic devices that treat acute viral conditions, chronic viral diseases and pathogens targeted as potential biological warfare agents. The Hemopurifier(R) combines the established scientific principles of affinity chromatography and hemodialysis as a means to mimic the immune system's response of clearing viruses and toxins from the blood before cell and organ infection can occur. The Hemopurifier(R) cannot cure viral conditions but can prevent virus and toxins from infecting unaffected tissues and cells. The company has completed pre-clinical blood testing of the Hemopurifier(R) to treat HIV and Hepatitis-C, and have completed human safety trials on Hepatitis-C infected patients in India.

Key Statistics

Overview:

Market Capitalization, $K 6,347
Enterprise Value, $K 907
Shares Outstanding, K 13,900
Annual Sales, $ 0 K
Annual Net Income, $ -12,210 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -2,430 K
EBIT, $ -12,650 K
EBITDA, $ -12,290 K
60-Month Beta 1.64
% of Insider Shareholders 4.00%
% of Institutional Shareholders 1.99%
Float, K 13,344
% Float 96.00%
Short Volume Ratio 0.52

Growth:

1-Year Return -89.33%
3-Year Return -99.17%
5-Year Return -99.08%
5-Year Revenue Growth -100.00%
5-Year Earnings Growth 90.47%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.91 on 06/27/24
Next Earnings Date 08/08/24
Earnings Per Share ttm -4.80
EPS Growth vs. Prev Qtr 33.58%
EPS Growth vs. Prev Year 17.27%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-10 on 10/05/23

AEMD Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -132.67%
Return-on-Assets % -103.20%
Profit Margin % 0.00%
Debt/Equity 0.00
Price/Sales N/A
Price/Cash Flow N/A
Price/Book 0.19
Book Value/Share 2.19
Interest Coverage -0.03
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar